MedTrace Logo

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

NCT06249438 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-07-25

No results posted yet for this study

Summary

This is an investigator-initiated, multicenter, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy

Conditions

  • Systemic Lupus Erythematosus (SLE)
  • Immune-mediated Necrotizing Myopathy (IMNM)
  • Neuromyelitis Optica Spectrum Disorders (NMOSD)
  • Multiple Sclerosis (MS)
  • Myasthenia Gravis
  • Systemic Sclerosis (SSc)

Interventions

BIOLOGICAL

CD20/BCMA-directed CAR-T cells

Autologous 2nd generation CD20/BCMA-directed CAR-T cells, single infusion intravenously

Sponsors & Collaborators

  • AbelZeta Pharma Inc.

    collaborator UNKNOWN

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Nan Shen, MD & PhD · Department of Rheumatology, RenJi Hospital, School of Medicine, Shanghai JiaoTong University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-20
Primary Completion
2027-03-31
Completion
2040-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06249438 on ClinicalTrials.gov